2026-03-26
22 分钟Hello, I'm Stephen Carroll.
I'm in Brussels, where many of Europe's biggest decisions get made.
And I'm Caroline Hepker in London.
We're the hosts of the Bloomberg Daybreak Europe podcast.
We're up early every weekday, keeping an eye on what's happening across Europe and around the world.
We do it early so the news is fresh, not recycled, and so you know what actually matters as the day gets going.
From Brussels, I'm following the politics, policy and the people shaping the European Union right now.
And from London, I'm looking at what all that means for markets, money and the wider economy.
We've got reporters across Europe and around the globe feeding in as stories break.
So whether it's geopolitics, energy, tech or markets, you're hearing it while it happens.
It's smart, calm and to the point.
And it fits into your morning.
You can find new episodes of the Bloomberg Daybreak Europe podcast by 7am in Dublin or 8am in Brussels,
Berlin and Paris.
On Apple, Spotify, YouTube, or wherever you get your podcasts.
We need to talk about the M&A deal that has come out in New York this morning.
Merck to buy Terns Pharmaceuticals for $6.7 billion to grow in the blood cancer space.
Michelle Davis is our senior deals reporter here in New York and is covering this story for us.
I feel like we should call it M&A Wednesday now because the deals no longer happen on Monday anymore.
You know, it's because we have a deal show now.